Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Pathogenesis 2

Study Overview
=================
Brief Summary
-----------------
The overall goal of this study is to identify risk and prognosis factors of Interstitial Lung Disease (ILD) in patients with rheumatoid arthritis (RA).

Detailed Description
-----------------
This is not an interventional study. This is a study designed to recruit individuals affected by RA and investigate associated ILD to better understand the clinical phenotypes and genetic/molecular endotypes of RAILD, including the prognosis of the disease.

Official Title
-----------------
Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Pathogenesis 2

Conditions
-----------------
Rheumatoid Arthritis, Interstitial Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
SELECTION OF CASES : Inclusion Criteria: Age ≥18 years RA diagnosis according to ACR (classification of rheumatoid arthritis) 1987 and/or ACR/EULAR 2010 criteria, validated by a senior rheumatologist ILD diagnosis based on typical High-Resolution Computed-Tomography (HCRT) patterns and pulmonary function tests (PFT), validated by a senior pulmonologist Exclusion Criteria: - Lack of signed informed consent SELECTION OF CONTROLS: Inclusion Criteria: Age ≥18 years RA diagnosis according to ACR 1987 and/or ACR/EULAR 2010 criteria, validated by a senior rheumatologist Exclusion Criteria: - Lack of signed informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rheumatoid arthritis - Interstitial lung disease patients<br>Assessment are as follows : Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment) Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance Radiologic: chest HRCT scan Genetic: DNA, mRNA Biologic: serum | |
| Rheumatoid arthritis - no Interstitial lung disease patients<br>Assessment are as follows : Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment) Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance Radiologic: chest HRCT scan Genetic: DNA, mRNA Biologic: serum | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of genetic factors implicated in RA-ILD using whole exome sequencing (WES). | whole exome sequencing data | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of genetic factors implicated in RA-ILD using genome wide association study. | genome wide sequencing data | Baseline | 
| Describe RA-ILD natural history by a 5 years annual follow up of RA-ILD patients. | Decline of pulmonary functional tests (PFT) as well as changes in High-Resolution Computed-Tomography chest scan scores | Every year during 5 years | 
| Description of the effect of disease modifying Anti Rheumatic Drugs (DMARDs) on ILD course and mortality. | Influence of treatment (DMARDs and biologics) over RA-ILD course estimated annually given the cumulated dosage received. | Every year during 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rheumatoid Arthritis, Interstitial lung disease